Metastatic pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumours
despite the use of multi-agent conventional chemotherapy regimens. Such poor outcomes …

Macrophages are a diverse set of cells present in all body compartments. This diversity is
imprinted by their ontogenetic origin (embryonal versus adult bone marrow–derived cells); …

Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second deadliest
cancer in the United States by 2025, with 5-year survival at less than 10%. In other …

Research on obesity-and diabetes mellitus (DM)-related carcinogenesis has expanded
exponentially since these two diseases were recognized as important risk factors for …

Metaplasia is the replacement of one differentiated somatic cell type with another
differentiated somatic cell type in the same tissue. Typically, metaplasia is triggered by …

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy. PDAC is only
cured by surgical resection in its early stage, but there remains a relatively high possibility of …

Although the estimated time for development of pancreatic ductal adenocarcinoma (PDA) is
more than 20 years, PDAs are usually detected at late, metastatic stages. PDAs develop …

Pancreatic ductal adenocarcinoma (PDA) is accompanied by reprogramming of the local
microenvironment, but changes at distal sites are poorly understood. We implanted …

Pancreatic Ductal Adenocarcinoma (PDAC) is projected to become the 2nd leading cause of
cancer-related deaths in the United States. Limitations in early detection and treatment …

Simple Summary There is currently no effective treatment for Pancreatic Ductal
Adenocarcinoma (PDAC), and it is still the deadliest cancer, despite great research efforts in …